Læknablaðið - 15.02.1999, Qupperneq 21

LÆKNABLAÐIÐ 1999; 85
119
Recommendations of the Task Force of the European
Society of Cardiology, European Atherosclerosis Society
and European Society of Hypertension. Eur Heart J 1994;
15: 1300-31.
9. 27th Bethesda Conference. Matching the Intensity of Risk
Factor Management with the Hazard for Coronary Disease
Events. September 14-15, 1995. J Am Coll Cardiol 1996;
27: 957-1047.
10. National Cholesterol Education Program. Second Report of
the Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment
Panel II). Circulation 1994; 89: 1333-5.
11. Þorgeirsson G, Sigurðsson G, Högnason J, Helgason S.
Blóðfitulækkandi lyfjameðferð. Læknablaðið 1996; 82:
734-5.
12. Sigurdsson E, Sigfusson N, Agnarsson U, Sigvaldason H,
Thorgeirsson G. Long-term prognosis of different forms of
coronary heart disease: the Reykjavik Study. Int J Epi-
demiol 1995;24:58-68.
13. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rif-
kind BM, et al. Ten-year mortality from cardiovascular dis-
ease in relation to cholesterol level among men with and
without preexisting cardiovascular disease. N Engl J Med
1990; 322: 1700-7.
14. Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman
AH, Reiber JH, Bruschke AV, et al. Effects of lipid lowering
by pravastatin on progression and regression of coronary
artery disease in symptomatic men with normal to mode-
rately elevated serum cholesterol levels. The regression
growth evaluation statin study. (REGRESS). Circulation
1995;91:2528-40.
15. Þorgeirsson G, Sigurðsson G, Sigurðsson JÁ, Högnason J,
Sverrisson JÞ, Guðmundsson ÞV, Ólafsdóttir E. Meðferð
við hárri blóðfitu. Læknablaðið 1991; 77: 59-60.
16. Brown WV. Hypercholesterolemia in the United States:
how far have we come? Am J Med 1997; 102: 3-6.
17. Marcelino JJ, Feingold KR. Inadequate treatment with
HMG-CoA reductase inhibitors by health care providers.
AmJMed 1996; 100: 605-10.
18. Cohen MV, Byme MJ, Levine B, Gutowski T, Adelson R.
Low rate of treatment of hypercholesterolemia by cardio-
logists in patients with suspected and proven coronary
artery disease. Circulation 1991; 83: 1297-304.
19. Moher M, Schofield T, Weston S,Fullard E. Managing es-
tablished coronary heart disease. BMJ 1997; 315: 69-70.
20. Pearson TA, Peters TD. The treatment gap in coronary artery
disease and heart failure: community standards and the post-
discharge patient. Am J Cardiol 1997; 80: 45H-52H.
21. Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM.
Secondary prevention in coronary heart disease: baseline
survey of provision in general practice. BMJ 1998; 316:
1430-4.
22. Pearson TA, Laurora IM. Attainment of LDL-cholesterol
goals in a national sample. Results from the Lipid Treat-
ment Assessment Project (L-TAP). JACC 1998; 31/Suppl.
A: 88A.
23. Steingart RM, Packer M, Hamm P, Coglianese ME, Gersh
B, Geltman EM, et al. Sex differences in the management of
coronary artery disease. Survival and Ventricular En-
largement Investigators. N Engl J Med 1991; 325: 226-30.
24. Ayanian JZ, Epstein AM. Differences in the use of pro-
cedures between women and men hospitalized for coronary
heart disease. N Engl J Med 1991; 325: 221-5.